← Back to Clinical Trials
Recruiting NCT06503588

NCT06503588 Ureteral Stent Exchange Abstention in Urinary Tract Infections

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06503588
Status Recruiting
Phase
Sponsor Central Hospital, Nancy, France
Condition Urinary Tract Infections
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2024-07-01
Primary Completion 2025-03-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Guidelines promoting surgical abstention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2024-07-01 with a primary completion date of 2025-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Committee of Infectiology of the French Association of Urology (CIAFU) provided, for the first time in 2020, comprehensive guidelines for ureteral stent-associated urinary tract infections (USAUTI) prevention, diagnosis and treatment. Since evidence lacked in terms of appropriate treatment, guidelines could not support systematic change of US in case of USAUTI. This study aims to evaluate whether "after guidelines group" patients treated for USAUTI had different occurrence of at least one relapse or recurrence than "before guidelines group".

Eligibility Criteria

Inclusion Criteria: * All patients with indwelling ureteral catheter * AND confirmed or probable urinary tract infection Exclusion Criteria: * Patient's opposition * History of ileal conduit urinary diversion * Second or more urinary tract infection during the study period

Contact & Investigator

Central Contact

Benjamin Lefevre, M.D. PhD

✉ b.lefevre@chru-nancy.fr

📞 +33383154097

Principal Investigator

+33383154097 Lefevre, M.D. PhD

PRINCIPAL INVESTIGATOR

Central Hospital, Nancy, France

Frequently Asked Questions

Who can join the NCT06503588 clinical trial?

This trial is open to participants of all sexes, studying Urinary Tract Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06503588 currently recruiting?

Yes, NCT06503588 is actively recruiting participants. Contact the research team at b.lefevre@chru-nancy.fr for enrollment information.

Where is the NCT06503588 trial being conducted?

This trial is being conducted at Nancy, France.

Who is sponsoring the NCT06503588 clinical trial?

NCT06503588 is sponsored by Central Hospital, Nancy, France. The principal investigator is +33383154097 Lefevre, M.D. PhD at Central Hospital, Nancy, France. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology